Journal ArticleDOI
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
Claus Garbe,Ketty Peris,Axel Hauschild,Philippe Saiag,Mark R. Middleton,Alain Spatz,Jean-Jacques Grob,Josep Malvehy,Julia Newton-Bishop,Alexander J. Stratigos,Hubert Pehamberger,Alexander M.M. Eggermont +11 more
Reads0
Chats0
TLDR
Recommendations on CM diagnosis and treatment are made based on systematic literature reviews and the experts' experience, with a clear survival benefit and the presence of toxicity limit its use in practice.About:
This article is published in European Journal of Cancer.The article was published on 2010-01-01. It has received 358 citations till now. The article focuses on the topics: Lymphadenectomy & Adjuvant therapy.read more
Citations
More filters
Journal ArticleDOI
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B. Faries,John F. Thompson,Alistair J. Cochran,Robert H.I. Andtbacka,Nicola Mozzillo,Jonathan S. Zager,Tiina Jahkola,Tawnya L. Bowles,Alessandro Testori,Peter D. Beitsch,Harald J. Hoekstra,Marc Moncrieff,Christian Ingvar,Michel W.J.M. Wouters,Michael S. Sabel,Edward A. Levine,Doreen M. Agnese,Michael A. Henderson,Reinhard Dummer,Carlo Riccardo Rossi,Rogerio I. Neves,Steven D. Trocha,Frances C. Wright,David R. Byrd,Maurice Matter,Eddy Hsueh,Alastair MacKenzie-Ross,Douglas B. Johnson,Patrick Terheyden,Adam C. Berger,Tara L. Huston,Jeffrey D. Wayne,B. Mark Smithers,Heather B. Neuman,Schlomo Schneebaum,Jeffrey E. Gershenwald,Charlotte E. Ariyan,Darius C. Desai,Lisa K. Jacobs,Kelly M. McMasters,Anja Gesierich,Peter Hersey,Steven D. Bines,John M. Kane,Richard J. Barth,Gregory McKinnon,Jeffrey M. Farma,Erwin S. Schultz,Sergi Vidal-Sicart,Richard A. Hoefer,James M. Lewis,Randall P. Scheri,Mark C. Kelley,Omgo E. Nieweg,R. Dirk Noyes,Dave S.B. Hoon,He-Jing Wang,David Elashoff,Robert Elashoff +58 more
TL;DR: Immediate completion lymph‐node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma‐specific survival among patients with melanoma and sentinel‐node metastases.
Journal ArticleDOI
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur,Paul B. Chapman,Caroline Robert,James Larkin,John B. A. G. Haanen,Reinhard Dummer,Antoni Ribas,David Hogg,Omid Hamid,Paolo A. Ascierto,Claus Garbe,Alessandro Testori,Michele Maio,Paul Lorigan,C. Lebbé,Thomas Jouary,Dirk Schadendorf,Stephen J O'Day,John M. Kirkwood,Alexander M.M. Eggermont,Brigitte Dréno,Jeffrey A. Sosman,Keith T. Flaherty,Ming Yin,Ivor Caro,Suzanne Cheng,Kerstin Trunzer,Axel Hauschild +27 more
TL;DR: An extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF (V600K) mutation subgroups is presented, finding that overall survival and progression-free survival was significantly longer in the vemurafenib group than in the dacarbazine group.
Journal ArticleDOI
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012
Claus Garbe,Ketty Peris,Axel Hauschild,Philippe Saiag,Mark R. Middleton,Alan Spatz,Jean-Jacques Grob,Josep Malvehy,Julia Newton-Bishop,Alexander J. Stratigos,Hubert Pehamberger,Alexander M.M. Eggermont +11 more
TL;DR: Therapeutic decisions in stage IV patients should be primarily made by an interdisciplinary oncology team ('Tumour Board'), based on systematic literature reviews and experts' experience.
Journal ArticleDOI
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
TL;DR: Advances in the understanding of the mechanism of chemotherapy resistance offer the hope for improved results with chemotherapy, and the triumvirate of more effective chemotherapy, immunotherapy, and targeted therapy are likely to be combined with one another for significant advances in melanoma over the coming few years.
Journal ArticleDOI
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs,Jose Luis Perez-Gracia,Ana Rouzaut,Miguel F. Sanmamed,Agnes Le Bon,Ignacio Melero +5 more
TL;DR: Type I interferons are well-known inducers of tumor cell apoptosis and antiangiogenesis via signaling through a common receptor interferon alpha receptor (IFNAR), and cross-talk between IFNAR and the pathways turned on by other surface lymphocyte receptors has been described.
References
More filters
Journal ArticleDOI
Technical details of intraoperative lymphatic mapping for early stage melanoma.
Donald L. Morton,D. R. Wen,Jan H. Wong,James S. Economou,Leslie A. Cagle,F K Storm,Leland J. Foshag,Alistair J. Cochran +7 more
TL;DR: Patients with early stage melanoma who have nodal metastases and are likely to benefit from radical lymphadenectomy are identified, with a high degree of accuracy, by a new procedure developed using vital dyes.
Journal ArticleDOI
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Charles M. Balch,Antonio C. Buzaid,Seng Jaw Soong,Michael B. Atkins,Natale Cascinelli,Daniel G. Coit,Irvin D. Fleming,Jeffrey E. Gershenwald,Alan Houghton,John M. Kirkwood,Kelly M. McMasters,Martin F. Mihm,Donald L. Morton,Douglas S. Reintgen,M. I. Ross,Arthur J. Sober,John A. Thompson,John F. Thompson +17 more
TL;DR: This revision of the staging system for cutaneous melanoma will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.
Journal ArticleDOI
Distinct Sets of Genetic Alterations in Melanoma
John A. Curtin,Jane Fridlyand,Toshiro Kageshita,Hetal N. Patel,Klaus J. Busam,Heinz Kutzner,Kwang Hyun Cho,Setsuya Aiba,Eva B. Bröcker,Philip E. LeBoit,Daniel Pinkel,Boris C. Bastian +11 more
TL;DR: The genetic alterations identified in melanoma at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Journal ArticleDOI
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Charles M. Balch,Seng Jaw Soong,Jeffrey E. Gershenwald,John F. Thompson,Douglas S. Reintgen,Natale Cascinelli,Marshall M. Urist,Kelly M. McMasters,M. I. Ross,John M. Kirkwood,Michael B. Atkins,John A. Thompson,Daniel G. Coit,David R. Byrd,Renee A. Desmond,Yuting Zhang,Ping-Yu Liu,Gary H. Lyman,Aberto Morabito +18 more
TL;DR: The proposed tumor-node-metastases categories and stage groupings for cutaneous melanoma patients were validated and incorporated into the AJCC melanoma staging as described in the companion publication.
Journal ArticleDOI
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
David W. Andrews,Charles B. Scott,Paul W. Sperduto,Adam E. Flanders,Laurie E. Gaspar,Michael C. Schell,Maria Werner-Wasik,W. Demas,J. Ryu,Jean-Paul Bahary,Luis Souhami,Marvin Rotman,Minesh P. Mehta,Walter J. Curran +13 more
TL;DR: WBRT and stereotactic radiosurgery should, therefore, be standard treatment for patients with a single unresectable brain metastasis and considered for Patients with two or three brain metastases.
Related Papers (5)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch,Jeffrey E. Gershenwald,Seng-Jaw Soong,John F. Thompson,Michael B. Atkins,David R. Byrd,Antonio C. Buzaid,Alistair J. Cochran,Daniel G. Coit,Shouluan Ding,Alexander M.M. Eggermont,Keith T. Flaherty,Phyllis A. Gimotty,John M. Kirkwood,Kelly M. McMasters,Martin C. Mihm,Donald L. Morton,Merrick I. Ross,Arthur J. Sober,Vernon K. Sondak +19 more
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Charles M. Balch,Seng Jaw Soong,Jeffrey E. Gershenwald,John F. Thompson,Douglas S. Reintgen,Natale Cascinelli,Marshall M. Urist,Kelly M. McMasters,M. I. Ross,John M. Kirkwood,Michael B. Atkins,John A. Thompson,Daniel G. Coit,David R. Byrd,Renee A. Desmond,Yuting Zhang,Ping-Yu Liu,Gary H. Lyman,Aberto Morabito +18 more